The number of DTC and Cluster buses seat up to 40 passengers. There are around 3,800 buses run by the DTC and over 2,600 run under Cluster scheme of Delhi Integrated Multi Modal Transit System.
Amid a spike in COVID-19 cases, Delhi Transport Minister Kailash Gahlot on Saturday said passengers can travel on all seats of public transport buses from November 1, and cautioned that travellers will have to wear face masks and maintain physical distancing. Gahlot, however, said no passengers will be allowed to travel in standing position. With the rise in number of COVID-19 cases, Delhi government had in May fixed the number of maximum passenger in Delhi Transport Corporation (DTC) and Cluster scheme buses to 20.
Lt Governor Anil Baijal, who is the chairman of Delhi Diaster Management Authority (DDMA) recently gave approval to Delhi government's proposal to run the public transport buses with full seating capacity. In a tweet, Gahlot said bus travellers will require to wear face masks and appealed to people to observe proper physical distancing in view of the COVID-19 threat.
"The passengers can travel on all the seats of buses from tomorrow. No passenger, however, will be allowed to travel in standing position. Wearing mask is compulsory and I appeal to all the travellers to maintain social distance to check the spread of Corona virus," Gahlot tweeted. With the opening of various economic activities and government and private establishments in the city, people were forced to wait in long queues often at crowded bus stands, due to restricted number of passengers in buses.
The number of DTC and Cluster buses seat up to 40 passengers. There are around 3,800 buses run by the DTC and over 2,600 run under Cluster scheme of Delhi Integrated Multi Modal Transit System. The DDMA chairman had also approved the proposal of the Transport department to resume inter-state bus service.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.